In March 2025, the company introduced new strategies for a immediate-to-client giving of its Wegovy weight loss drug. The company recognized a different pharmacy, termed NovoCare, which would demand shoppers $499 monthly for entry to the drug, fewer than 50 % the cost of the drug by means of other pharmaceutical distribution networks.[fifty three]A